Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 07, 2019 07:30 ET | Source: Pacira BioSciences

Phase 4 Study Demonstrates Superiority of EXPAREL plus Bupivacaine versus Bupivacaine Alone in Cesarean Section Procedures

– TAP block with EXPAREL provides significant reductions in opioids and pain scores – – Results presented at Society of Obstetric Anesthesia and Perinatology annual meeting – PARSIPPANY, N.J.,...
May 02, 2019 08:00 ET | Source: Pacira BioSciences

Pacira BioSciences Reports First Quarter 2019 Revenues of $91.3 Million

-- EXPAREL® net product sales of $90.6 million up 22.4 percent over prior year first quarter -- -- MyoScience acquisition advances leadership in non-opioid pain management; corporate name change to...
April 25, 2019 07:30 ET | Source: Pacira BioSciences

Pacira to Report First Quarter 2019 Financial Results on Thursday May 2, 2019

PARSIPPANY, N.J., April 25, 2019 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its first quarter financial results before the open of the U.S....
April 09, 2019 16:01 ET | Source: Pacira Pharmaceuticals, Inc.

Pacira Completes Acquisition of MyoScience, Advancing Leadership in Non-opioid Pain Management with FDA-approved ioveraº System

-- Adds highly complementary cryoanalgesia treatment to commercial offering -- -- New corporate name of Pacira BioSciences reflects expanding product portfolio -- PARSIPPANY, N.J., April 09, 2019 ...
April 02, 2019 07:30 ET | Source: Pacira Pharmaceuticals, Inc.

Pacira Pharmaceuticals to Present at the 18th Annual Needham Healthcare Conference

PARSIPPANY, N.J., April 02, 2019 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today reported that it will present at the 18th Annual Needham Healthcare Conference at 3:30 PM ET on...
March 13, 2019 07:30 ET | Source: Pacira Pharmaceuticals, Inc.

New Analysis Shows Enhanced Recovery Pathway Including EXPAREL Infiltration Facilitates Rapid Discharge, High Satisfaction, and Limited Opioid Use in Medicare Patients Undergoing Total Joint Replacement

PARSIPPANY, N.J., March 13, 2019 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced new data showing that a patient-optimizing, opioid-sparing enhanced recovery after...
March 05, 2019 07:00 ET | Source: Pacira Pharmaceuticals, Inc.

Pacira to Acquire MyoScience, Adding FDA-approved ioveraº System for Non-opioid Pain Control

-- Novel cryoanalgesia treatment highly complementary to EXPAREL -- -- Corporate name change to Pacira BioSciences to reflect expanding product portfolio -- -- Conference call today at 8:30 AM ET --...
February 28, 2019 08:00 ET | Source: Pacira Pharmaceuticals, Inc.

Pacira Reports Record Fourth Quarter and Full Year Revenues

-- Increasing adoption of EXPAREL® Across Opioid-Sparing Pain Management Protocols -- -- EXPAREL net product sales expected to be in the range of $400M to $410M in 2019 -- -- Conference call today...
February 21, 2019 07:30 ET | Source: Pacira Pharmaceuticals, Inc.

Pacira to Report 2018 Financial Results on Thursday February 28, 2019

PARSIPPANY, N.J., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that it will report its fourth quarter and year ended December 31, 2018 financial...
February 12, 2019 07:30 ET | Source: Pacira Pharmaceuticals, Inc.

Pacira Expands EXPAREL Manufacturing Capacity to Meet Growing Demand

PARSIPPANY, N.J., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that commercial production of EXPAREL® (bupivacaine liposome injectable suspension) is...